Literature DB >> 26975445

Prevalence and pattern of humoral immunodeficiency in chronic refractory sinusitis.

Haitham Odat1, Mohannad Alqudah2.   

Abstract

The purpose of this study is to readdress the issue of primary humoral immunodeficiency frequency and pattern in medically resistant chronic rhinosinusitis (CRS) based on the new guidelines for CRS diagnosis and management. Two hundred and fifty-seven consecutive patients with refractory CRS were included in this study. The results of their IgA, IgM, IgG, and IgG subclasses were analyzed and compared with 75 age- and gender-matched control groups. The average age of CRS patients was 34 years (SD ± 13). In the refractory CRS group, there was no significant difference between patients with or without humoral immunodeficiency based on age, gender and status of allergy, polyps and revision. Low level of one of the major immunoglobulin isotypes was found in 15 patients (6 %). Six patients had low IgG, two had low IgA, and seven had low IgM. IgG subclasses were low in 37 patients (14 %), and IgG4 was the most common deficient subclass. Multiple immunoglobulins deficiencies were found in eight patients. Compared with the control group, CRS patients had a significant higher prevalence of major immunoglobulins as well as total major immunoglobulins and IgG subclasses deficiency. Because of high prevalence of subtle humoral immunodeficiency in medically resistant CRS and inability to find unique clinical and demographic characteristic of these patients, we recommend routine screening of major immunoglobulins and IgG subclasses on the group of CRS patients who failed medical treatment.

Entities:  

Keywords:  Deficiency; Immunoglobulin; Pattern; Prevalence; Rhinosinusitis; Subclasses

Mesh:

Substances:

Year:  2016        PMID: 26975445     DOI: 10.1007/s00405-016-3981-x

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Medical management in functional endoscopic sinus surgery failures.

Authors:  James N Palmer; David W Kennedy
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2003-02       Impact factor: 2.064

Review 3.  Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology.

Authors:  Michael S Benninger; Berrylin J Ferguson; James A Hadley; Daniel L Hamilos; Michael Jacobs; David W Kennedy; Donald C Lanza; Bradley F Marple; J David Osguthorpe; James A Stankiewicz; Jack Anon; James Denneny; Ivor Emanuel; Howard Levine
Journal:  Otolaryngol Head Neck Surg       Date:  2003-09       Impact factor: 3.497

4.  Rhinosinusitis: Developing guidance for clinical trials.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Allen D Adinoff; Claus Bachert; Larry Borish; Vernon M Chinchilli; Melvyn R Danzig; Berrylin J Ferguson; Wytske J Fokkens; Stephen G Jenkins; Valerie J Lund; Mahmood F Mafee; Robert M Naclerio; Ruby Pawankar; Jens U Ponikau; Mark S Schubert; Raymond G Slavin; Michael G Stewart; Alkis Togias; Ellen R Wald; Birgit Winther
Journal:  Otolaryngol Head Neck Surg       Date:  2006-11       Impact factor: 3.497

5.  The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis.

Authors:  L Vanlerberghe; S Joniau; M Jorissen
Journal:  B-ENT       Date:  2006       Impact factor: 0.082

6.  Reduced immunoglobulin M is associated with sinus mucosal thickening, osteitis and sinus surgery in patients with common variable immunodeficiency.

Authors:  John B Hagan; Miguel A Park; Hirohito Kita; Norbert G Campeau
Journal:  Int Arch Allergy Immunol       Date:  2009-11-24       Impact factor: 2.749

Review 7.  Immunodeficiency in chronic sinusitis: recognition and treatment.

Authors:  Whitney W Stevens; Anju T Peters
Journal:  Am J Rhinol Allergy       Date:  2015 Mar-Apr       Impact factor: 2.467

8.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

9.  Clinical and immunological features in IgM deficiency.

Authors:  Leman Yel; Srinivasan Ramanuja; Sudhir Gupta
Journal:  Int Arch Allergy Immunol       Date:  2009-06-04       Impact factor: 2.749

Review 10.  Antibody deficiency in chronic rhinosinusitis: epidemiology and burden of illness.

Authors:  Christopher J Ocampo; Anju T Peters
Journal:  Am J Rhinol Allergy       Date:  2013-01       Impact factor: 2.467

View more
  4 in total

Review 1.  Immune deficiency in chronic rhinosinusitis: screening and treatment.

Authors:  Sergio E Chiarella; Leslie C Grammer
Journal:  Expert Rev Clin Immunol       Date:  2016-08-18       Impact factor: 4.473

2.  [Immunodeficiency in chronic rhinosinusitis : An important and often underestimated cause].

Authors:  L Klimek; A Chaker; C Matthias; A Sperl; P Gevaert; P Hellings; B Wollenberg; M Koennecke; J Hagemann; J Eckrich; S Becker
Journal:  HNO       Date:  2019-09       Impact factor: 1.284

3.  Aeroallergen sensitization profile in medically resistant chronic rhinosinusitis.

Authors:  Haitham Odat; Maulla Alali; Mohannad Al-Qudah
Journal:  SAGE Open Med       Date:  2020-06-25

4.  Duration of frequent or severe respiratory tract infection in adults before diagnosis of IgG subclass deficiency.

Authors:  James Barton; Clayborn Barton; Luigi Bertoli
Journal:  PLoS One       Date:  2019-05-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.